Daily Program

/Daily Program
Daily Program 2018-03-13T13:35:57+00:00

PRELIMINARY. Exact schedule times to be advised

Tuesday, May 15, 2018

07:30  -  17:00

Registration Open

    09:30  -  09:50
    Hall A

    Welcome by Conference Co-Chairpersons

      Ruti Alon, Founder and CEO, Medstrada
      Ora Dar, PhD, Israel Innovation Authority
      Nissim Darvish, MD, PhD, Senior Managing Director, OrbiMed

      09:50  -  11:20
      Hall A

      Plenary Session

        09:50-10:35 Arie S. Belldegrun MD, FACS, Founder, Kite Pharma; Executive Chairman & Co-Founder, Allogene Therapeutics

        10:35-11:20 Francois Maisonrouge, Senior Managing Director, Evercore Partners

        11:20  -  11:50

        Coffee Break

          Hall A

          Next Generation Oncology Treatments

            Chair: Prof. David Sidransky, MD, Johns Hopkins School of Medicine and Israel Biotech Fund, Co-Founder and General Partner

            Tal Zaks, MD, PhD, Chief Medical Officer Moderna Therapeutics: “Translating mRNA vaccines and therapeutics into IO agents”

            Prof. Jeffrey A. Sosman, MD, Director, Melanoma program, Director Faculty Development, Co-Leader, Translational Research in Solid Tumors, Robert H. Lurie Comprehensive Cancer Center of Northwestern University

            Alan Wise, PhD, CEO, IOmet Pharma (a wholly-owned subsidiary of MSD):  “MSD Immuno-Oncology Overview”

            Hall B

            Gene Editing, Rare Genetic Diseases and Gene Therapy

              Chair: Yael Weiss, MD, PhD, Vice President Business Development, Ultragenyx

              Dror Haratz, MD, Chief Executive Officer, Vascular Biogenics: “Gene Therapy”

              Panel: Rare disease:
              Moderator: Yael Weiss, MD, PhD, Vice President Business Development, Ultragenyx

              Julia Hawkins, Partner, LocalGlobe
              “MiaMed (CDKL5 deficiency)”
              Tauhid Ali, PhD, Vice President and Head of TAK-celerator, Takeda
              Chris Adams, PhD, MBA, Chief Executive Officer, Cydan II Inc.
              Daniel Fischer, Founder at Tevard Biosciences

              Hall C

              Novel Clinical Trial Designs and Technologies to Accelerate Drug Development

                Chair: Iris Grossman, PhD, CEO, IsraGene Ltd

                Iris Grossman, PhD, CEO, IsraGene Ltd: “Introduction”

                Erhan Bilal, PhD, IBM T.J. Watson Research / Computational Biology Center

                Marc Funk, COO & President, Lonza Pharma & Biotech

                Dan Vesely, Co-founder, CliniCrowd, Partner at Sdemagroup

                Daphna Laifenfeld, PhD, Head, Personalized Medicine & Diagnostics, Teva Pharmaceuticals

                Iris Grossman, PhD, CEO, IsraGene Ltd: “Closing Remarks”

                Wednesday, May 16, 2018

                09:30  -  09:50
                Hall A

                Plenary Session

                  Aharon Aharon, CEO, Israel Innovation Authority

                  09:50  -  10:50
                  Hall A

                  Corporate Panel

                    Moderator: David Cassak, Managing Partner, Innovation In Medtech

                    Michael Martin, PhD, Global Head, Takeda Ventures, Inc.
                    Zeev Zehavi, Vice President of Venture Investments, Johnson & Johnson Innovation – JJDC, Inc. (JJDC)
                    Gil Bar-Nahum, PhD, Managing Director, Jefferies International, London, UK
                    Michal Silverberg, Managing Director, Novartis Venture Fund
                    Chris Kaster, Vice President, Business Development, Venture Capital Investing, Boston Scientific
                    Simon Gisby, Managing Director, Deloitte Corporate Finance LLC
                    David Neustaedter, Vice President, Venture Capital Medtronic

                    10:50  -  11:30
                    Hall A

                    Plenary Session

                      Bruce R. Rosengard, MD, Chief Medical Science and Technology Officer, Johnson & Johnson Medical Devices Companies

                      11:30  -  12:00

                      Coffee Break

                        Hall A

                        Nanomedicine and its Role in New Medical Therapeutics

                          Chair: Prof. Simon Benita, PhD, Head of Nano Delivery Systems, Hebrew University of Jerusalem

                          Anand Subramony, PhD, Vice President, Novel Product Technologies, MedImmune: “Nanomedicine and its Role in New Medical Therapeutics”

                          Prof. Dina Ben-Yehuda, PhD, Dean, Hadassah-Hebrew University Faculty of Medicine “Targeted Nanoparticles for improved hematological cancers”

                          Prof. Ronit Satchi-Fainaro, PhD, Head, Cancer Angiogenesis and Nanomedicine Laboratory, Sackler Faculty of Medicine, Tel Aviv University: “Reverting cancer’s poor prognosis using precision nanomedicines based on molecular fingerprints of long-term vs short-term survivors“

                          Panel: Nanotechnology up-scaling Challenges: from bench to the market

                          Hall B

                          From Academic Research to Industry

                            Chair: Gil Granot-Mayer, CEO, Yeda R&D – Technology Transfer, Weizmann Institute of Science

                            Block 1 – Life Cycle of Technology Transfer – From Initial Disclosure to Success Story

                            Gil Granot-Mayer, CEO, YEDA; “Introduction”

                            Panel: Looking at both sides of the curtain with technology transfer – new technology transfer practices, the convergence of digital technology into the pharma world, commercializing platforms, and better understanding of what is driving TTO policy
                            Moderator: Mr. Benjamin Soffer, CEO, T3
                            Tamar Raz, CEO. Hadasit
                            Sylvie Luria, CEO Sheba
                            Yaron Daniely, CEO, Yissum
                            Shlomo Nimrodi, CEO, Ramot
                            Netta Cohen, CEO, BGN Technologies
                            Gil Granot-Mayer, CEO, Yeda
                            Larry Loev, CEO, Ariel Scientific Innovations

                            Showcase of new start-ups from academia Part 1 of 3
                            Moderator: Larry Loev, CEO, Ariel Scientific Innovations
                            Yitshak Francis, Scientific Advisor, Qrons; Ariel University
                            Yoram Eshel, CEO, On-Sight; Weizmann Institute of Science
                            Prof. Fuad Fares, Founder, CanCuRX; Haifa University
                            Jessica Weiss, CEO, Lydus Medical; Clalit

                            Major Israeli success stories in life sciences – Fireside chat with Professors who championed academic innovation into industry.
                            Moderator: Shay Sela, VP, Business Development of Life Sciences, YEDA
                            Prof. Michel Revel, MD, PhD, Professor Emeritus, Weizmann Institute of Science and Chief Scientist, Kadimastem Ltd
                            Prof. Yechezkel “Chezy” Barenholz, Hebrew University of Jerusalem and Founder of Numerous Startups
                            Prof. Moussa B.H. Youdim, Prof. Emeritus at the Technion, Founder of Numerous Startups, and President & Chief Scientific Officer at Youdim Pharmaceuticals
                            Prof. Avigidor Scherz, Weizmann Institute of Science and Developed the technology behind Steba BioTech

                            Block 2 – Creating the Environment for Successful Technology Transfer:

                            Funding and performing translational research – models in taking bench side research to market. (Collaboration with the IIA; Horizon 2020; NIH; Spark (Stanford) programs)
                            Moderator: Gil Granot-Mayer, CEO, YEDA
                            Michael Salgaller, Supervisor, Invention Development and Marketing Unit (IDMU), Technology Transfer Center, National Cancer Institute, National Institutes of Health
                            Pasi Sorvisto, Director, SPARK Finland Program
                            Esther Hagai, CEO, FutuRx
                            Prof. Eli Hazum, Head, IDEA program at YEDA
                            Aviv Zeevi Balasiano, VP, Head of Division – Technology Infrastructure Israel Innovation Authority
                            Eyal Zimlichman, Deputy Director General, Chief Medical Officer and Chief Innovation Officer at Sheba Medical Center

                            Showcase of new start-ups from academia Part 2 of 3
                            Moderator: Larry Loev, CEO, Ariel Scientific Innovations
                            Nadav Peles, Co-Founder, Acting CEO, Ta Geza; Sheba
                            Prof. Noam Shomron, CSO, Variantyx; TAU
                            Tomer Behor, CEO, RenewSenses; Hebrew University

                            View of the Israeli life science ecosystem – How do we realize the potential?
                            Moderator: Daphna Murvitz, Co-founder & CEO, 8400 Health Network
                            Zeev Zehavi, Vice President, Venture Investments JnJ
                            Prof. David Sidransky, MD, General Partner at the Israel Biotech Fund
                            Einat Zisman, Former CEO of FutuRx
                            Yuval Ofek, Founder & Chairman at DayTwo
                            Roni Mamluk, CEO at Ayala Pharmaceuticals
                            Itai Kela, Senior Director, Head of Healthcare and Biotechnology, Israel Innovation Authority

                            Showcase of new start-ups from academia Part 3 of 3
                            Moderator: Larry Love, CEO, Ariel Scientific Innovations
                            Daria Lemann-Blumenthal, CEO, Belkin Laser; Sheba
                            Hila Goldman Aslan, CEO, DiA Imaging Analysis; Ben Gurion University
                            Prof. Ayala Pollack, MD, Inventor & Medical Director, OphtimedRx; Clalit
                            Seth Salpeter, Co-Founder & CTO, CuResponse, Weizmann Institute of Science

                            Gil Granot-Mayer, CEO, YEDA; “Closing Remarks”

                            Hall C

                            Cutting Edge Medical Device Technologies: Metabolic, Ophthalmology

                              Metabolic Chair: Irit Yaniv, MD, General Partner, Accelmed

                              Ophthalmology Chair: Barak Azmon, MD, Managing Director, Notal Vision

                              Ophthalmic Panel:
                              Prof. Anat Loewenstein MD, MHA,  Head, Ophthalmology Division, Tel Aviv Medical Center
                              Prof. Ehud Assia, MD, Head, Ophthalmology Division, Meir Medical Center
                              Laurent Attias, Senior Vice President, Head of Strategy, BD&L and M&A
                              Barak Azmon, MD, Managing Director, Notal Vision

                              Thursday, May 17, 2018

                              09:10  -  09:25
                              Hall A

                              Winner of Startup Competition

                                Dr. Ami Appelbaum, Chairman IIA

                                09:25  -  11:25
                                Hall A

                                Plenary Session

                                  09:25-10:05 Philip Nelson, Director of Engineering at Google Research

                                  10:05-10:45 Paul R. Biondi, Senior Vice President, Head of Business Development, Bristol-Myers Squibb

                                  10:450-11:25 Troy Cox, Chief Executive Officer, Foundation Medicine

                                  11:25  -  11:50

                                  Coffee Break

                                    Hall A

                                    Digital Health, IoT, and Big Data – New Armamentarium in Medicine

                                      Co-Chairs: Anat Naschitz, Managing Director, Orbimed Advisors and Allen Kamer, Managing Partner, OurCrowd Qure

                                      John D. Halamka, MD, MS, Chief Information Officer, Beth Israel Deaconess System: “Emerging Innovations in Healthcare Information Technology”

                                      Joshua Milner, MD, Chief, Laboratory of Allergic Diseases, National Institute of Health: “Building a System and a Culture of Sharing in the Ever Blurring Line of Clinical and Research Genomics”

                                      Elie Lobel, CEO, Orange Healthcare: “Leveraging Technology & Data For Consumer’s Health Improvement”

                                      AI AND CYBER
                                      Ziv Ofek, Founder and CEO, MDClone
                                      Amir Magner, CEO, CyberMDX

                                      PATIENT DRIVEN CARE
                                      Ofer Tzadik, COO, TytoCare
                                      Ariel Beery, CEO, MobileODT
                                      Ran Shaul, Co-Founder and Chief Product Officer, K Health

                                      DATA AND BIOLOGY – A 2 WAY STREET
                                      Prof. Shai Shen-Orr, Chief Scientist, CytoReason; Faculty of Medicine, Technion
                                      Prof. Zohar Yakhini, DNA storage

                                      Hall B

                                      Personalized Diagnostics and Treatments

                                        Chair: Varda Shalev, MD, Managing Director, Morris Kahn & Maccabi Research and Innovation Institute at Maccabi Health Care Services

                                        Miro Venturi, PhD, Global Head – Diagnostics Biomarkers & Personalized Healthcare, F. Hoffmann-La Roche Ltd

                                        David Fenstermacher, PhD, VP R&D-Bioinformatics, Medimmune

                                        Prof. Gideon Rechavi, MD, PhD, Head, Sheba Cancer Research Center

                                        Shai Rosenberg, MD, Neuro-Oncology & Head of Cancer Computational Biology Lab., Hadassah-Hebrew University Medical center

                                        Randy J. Prebula, Partner, Hogan Lovells, Washington, D.C.

                                        Varda Shalev, MD, Managing Director, Morris Kahn & Maccabi Research & Innovation Institute at Maccabi Health Care Services

                                        Hall C

                                        Brain Health

                                          Chair: Tetsuyuki Maruyama, PhD, Chief Scientific Officer, Dementia Discovery Fund, SV Life Sciences Managers

                                          Tetsuyuki Maruyama, PhD, Chief Scientific Officer, Dementia Discovery Fund, SV Life Sciences Managers: “Where are we in Research, Treatment and Prevention of AD and Dementia “

                                          Prof. Nir Giladi, MD, Director, Neurology Division, Tel Aviv Sourasky Medical Center

                                          Panel: “Innovations in-development” to Improve treatment for Brain diseases – challenge the traditional drug development frameworks.

                                          Panel: Getting closer to validated Biomarkers
                                          Hartmuth Kolb, PhD, Head of Neuroscience Biomarkers, Janssen Research & Development
                                          Prof. John Gallacher, Director, Dementia Platform UK, University of Oxford